Board of Directors
Jeffrey L. Edwards Former Executive Vice President, Finance and Business Development & CFO of Allergan, Inc.
Jeffrey L. Edwards was appointed to our board of directors in 2015 after retiring from Allergan Inc., which he joined in 1993 and where he served as Executive Vice President, Finance and Business Development, Chief Financial Officer from September 2005 to August 2014. From 2003 to 2005, Mr. Edwards served as Allergan’s Corporate Vice President, Corporate Development, and previously served as Senior Vice President, Treasury, Tax, and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the board of directors and as Audit Committee Chairman of Viamet Pharmaceuticals Holdings, LLC, a privately owned biopharmaceutical company. Mr. Edwards received a B.A. in Sociology from Muhlenberg College and completed the Advanced Management Program at the Harvard Business School.
Jeffrey W. Henderson Former CFO of Cardinal Health, Inc.
Jeffrey W. Henderson has served on our board of directors since August 2015. Mr. Henderson has nearly 30 years of financial, commercial, and pharmaceutical industry experience. Most recently he served as Chief Financial Officer for Cardinal Health Inc. from 2005 until 2014. His many responsibilities at Cardinal Health included commercial operations in China. Prior to Cardinal Health, Mr. Henderson was President and General Manager of Eli Lilly Canada Inc. and Vice President and Corporate Controller of Eli Lilly & Company. He joined Eli Lilly in 1998 as Vice President and Corporate Treasurer. His prior experience includes 10 years at General Motors, where he served in executive and managerial posts in Great Britain, Singapore, New York, and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Michigan, and his M.B.A. from Harvard Graduate School of Business Administration. Mr. Henderson is a native of St. Catharines, Ontario, Canada. He is a director of Qualcomm Incorporated, Halozyme Therapeutics Inc., Integrated DNA Technologies Inc., and Affordable Care Inc. He is also an Advisory Director at the private equity firm of Berkshire Partners, LLC.
Thomas F. Kearns Jr. Retired Partner, Bear, Stearns & Co., Inc.
Thomas F. Kearns Jr. has served on our board of directors since November 1996. Mr. Kearns is a retired Partner of The Bear Stearns Companies, Inc., where he was an investment banker in the healthcare area from 1974 until 1987. Prior to his career at Bear Stearns, Mr. Kearns worked for Merrill Lynch from January 1959 until August 1969. Mr. Kearns is Chairman of the National Advisory Board of Carolina Performing Arts at the University of North Carolina. In 2013, he joined the board of directors of Franklin Street Partners. Mr. Kearns was a Trustee of the University of North Carolina Foundation and Endowment Fund for 16 years and served on the board of directors of Biomet Inc. from January 1980 until May 2005. He received his B.A. in History from the University of North Carolina.
Kalevi Kurkijärvi, Ph.D. Executive Chairman, Owner Innomedica Ltd., Former Chairman & CEO, Co-Founder Bio Fund Management Oy
Kalevi Kurkijärvi, Ph.D., has served on our board of directors since November 1996. He has also served on the board of directors of our subsidiary, FibroGen Europe Oy, since November 1997. Since March 2010, Dr. Kurkijärvi has been the Chairman and Founding Partner of Innomedica Oy, a business development company specialized in licensing, distributor search, and strategic planning for companies in the pharmaceutical and medtech industries, and from August 1997 to February 2010 he acted as Director, with financial matters as his main responsibility. He was also the Founding Partner and former Chairman and Chief Executive Officer of Bio Fund Management, a Finnish-Danish venture capital company, from 1997 until 2010. He has also been Chairman and Chief Executive Officer of his family’s import-export trading company, Biketex Ltd., since October 1993. Dr. Kurkijärvi has over twenty years of experience in international life science business and over ten years in corporate finance. He currently serves on the boards of directors of Innomedica Oy (chair), Biketex Ltd. (chair), and Hytest Oy (chair). He previously served on the boards of directors at other biotechnology companies such as Paratek Pharmaceuticals Inc., Ark Therapeutics Plc, BioTie Therapies Plc (chair), Stick Tech Oy (chair), Hormos Medical Oy (chair), Map Medical Oy (chair), Bio Orbit Oy (chair), and Juvantia Pharma Oy, among others. Prior to founding Bio Fund, Dr. Kurkijärvi worked as Executive Director of the venture capital group at the Finnish National Fund of Research and Development (SITRA). He has also served as Executive Vice President at Wallac Oy and as President and Chief Executive Officer of Pharmacia Diagnostics Production Oy. Dr. Kurkijärvi received a Ph.D. in Biochemistry and Molecular Biology from the University of Turku in 1992, where he also worked for several years in research and teaching.
Rory B. Riggs Managing Member, Balfour LLC; Former President and Director, Biomatrix, Inc.
Rory B. Riggs has served on our board of directors since October 1993. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax Analytics LLC, a development-stage venture focused on creating a new information technology platform for large-scale portfolio management. Mr. Riggs is co-founder and chairman of Royalty Pharma, the largest acquirer of drug royalties, and Cibus Global Ltd., the leading company in gene editing in agriculture. In addition, he sits on the boards of directors of Intra-Cellular Therapies Inc., Nuredis Inc., GeneNews Ltd., and eReceivables LLC (Chair). Since June 2006, Mr. Riggs has also served as Managing Member of New Ventures, a venture fund focused on biotechnology and healthcare. Mr. Riggs served as the President of Biomatrix Inc., a biomedical company, from 1996 until 2000. From 1991 to 1995, he was Chief Executive Officer of RF&P Corporation, an investment company owned by the Virginia Retirement System. He was also Managing Director of PaineWebber and Company, a stock brokerage and asset management firm, in the mergers and acquisitions field. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an M.B.A. from Columbia University.
Roberto Pedro Rosenkranz, Ph.D., M.B.A. Executive Chairman, Altos Therapeutics LLC; Director, Pherin Pharmaceuticals; Former Chairman and Chief Executive Officer, ROXRO PHARMA, Inc.
Roberto Pedro Rosenkranz, Ph.D., M.B.A. has served on our board of directors since April 2010. Dr. Rosenkranz was Chairman and Chief Executive Officer of ROXRO PHARMA Inc., a pharmaceutical company, from October 1999 to December 2010. Since 2012, he has been executive chairman of Altos Therapeutics LLC, a pharmaceutical company. Dr. Rosenkranz is also on the board of directors of Pherin Pharmaceuticals Inc., a pharmaceutical company, and the Ronald and Ann Williams Charitable Foundation. Prior to assuming his leadership role at ROXRO, Dr. Rosenkranz was President and Chief Operating Officer of Scios Inc., a biopharmaceutical company, from 1996 to 1997. From 1995 to 1996, he occupied multiple research, development, and marketing positions at Roche Laboratories, a pharmaceutical company. From 1982 to 1996, Dr. Rosenkranz occupied multiple research, development, and marketing positions at Syntex Laboratories Inc., a pharmaceutical company. Dr. Rosenkranz previously sat on the boards of Medcenter Solutions do Brasil SA and Gemini Genomics Limited (also referred to as Gemini Genomics Plc). Dr. Rosenkranz received a B.A. in Psychology from Stanford University, a Ph.D. in Pharmacology and Toxicology from U.C. Davis, and an M.B.A. from Santa Clara University.
Jorma Routti, Ph.D. Chairman of the Board of Directors, FibroGen Europe Oy, Former Director General of the Directorate of Science, Research and Development of the European Commission
Jorma Routti, Ph.D. has served on our board of directors since March 1994. He is also the Chairman of the board of directors of our subsidiary, FibroGen Europe Oy, and has served in that capacity since 2001. Since 2001, Dr. Routti has served as Executive Chairman of CIM Creative Industries Management Ltd., a venture capital firm located in Helsinki, Finland, where he works with investments and research in intellectual property oriented companies as well as with Knowledge Economy developments in several countries. Dr. Routti served, from 1995 to 2000, as Director General of Research of the European Commission, the executive body of the European Union. From 1985 to 1995, Dr. Routti served as President of SITRA, the Finnish Innovation Fund. Dr. Routti served as Dean and Professor at the Helsinki University of Technology from 1972 to 1985, as a scientist at CERN in Geneva from 1967 to 1972, and at the University of California, Berkeley. He has served on the boards of directors (including as chairman) of several major corporations, high technology companies, and international research establishments. Dr. Routti has received numerous honors including Fulbright and Eisenhower Exchange Fellowships and decorations in Finland and France. He received a Ph.D. in Physics from U.C. Berkeley as well as an M.Sc. in technical physics and a Dr.Techn h.c. in technology from the Helsinki University of Technology. Dr. Routti was awarded an honorary doctorate in philosophy from the University of Jyvaskyla, Finland.
James A. Schoeneck Former President and CEO, Depomed, Inc.
James A. Schoeneck has served on our board of directors since April 2010. Mr. Schoeneck was former Chief Executive Officer at Depomed, Inc., which he joined in 2007. From 2005-2007 he was Chief Executive Officer of BrainCells Inc., a privately-held biopharmaceutical company. Prior to joining BrainCells Inc. he served as Chief Executive Officer of ActivX BioSciences, a development-stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics company. Prior to joining Prometheus, Mr. Schoeneck spent three years as Vice President and General Manager, Immunology, at Centocor Inc. (now Janssen Biotech, Inc.), a biotechnology company, where he led the development of Centocor’s commercial capabilities. His group launched Remicade®, which became one of the world’s largest pharmaceutical brands. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. in Education from Jacksonville State University.
Toshinari Tamura, Ph.D. Former Representative Director, Executive Vice President and Chief Science Officer of Astellas Pharma, Inc.
Toshinari Tamura, Ph.D. has served on our board of directors since September 2008. He previously worked at Yamanouchi Pharmaceutical Co. Ltd., starting in 1972 and ultimately becoming Executive Corporate Officer and Representative Director. Following the merger with Astellas Pharma Inc., he was named Executive Vice President and Chief Science Officer of Astellas and served in those roles and on the board of directors from April 2005 until June 2008. Dr. Tamura was in charge of research and development of FibroGen’s PHI anemia program in 2004 and has remained familiar with the science of the program since then. Dr. Tamura served as director of the board of KinoPharma Inc., a drug development company, from September 2008 to March 2010. Dr. Tamura served as director of the board of IMMD Inc., a drug development company, from October 2010 to November 2012. Dr. Tamura served as an advisor to Shin Nippon Biomedical Laboratories Ltd., a drug development company, from September 2008 to August 2015. Dr. Tamura served as an advisor to Japan Science and Technology Agency, a government-sponsored organization promoting science and technology, from September 2012 to March 2015. Dr. Tamura is currently advisor to Innovation Network Corporation of Japan, a government-sponsored private equity firm (from February 2010), and Japan Agency for Medical Research and Development, a government-sponsored organization to promote integrated medical R&D (from April 2015). Dr. Tamura holds a Bachelor’s degree in Pharmaceutical Science from Chiba University, Department of Pharmaceutical Sciences, and Master’s and Ph.D. degrees in Organic Chemistry from the University of Tokyo, Graduate School of Pharmaceutical Sciences.